CytoDyn Inc.

CytoDyn Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for various medical conditions. The company's primary product candidate is leronlimab, also known as PRO 140, which is a humanized monoclonal antibody designed to target the C-C chemokine receptor type 5 (CCR5). Leronlimab is currently being investigated for its potential use in solid-tumor oncology. CytoDyn Inc. was originally incorporated in Colorado on May 2, 2002, as RexRay Corporation, and later reincorporated in Delaware on August 27, 2015. The company acquired PRO 140 from Progenics in October 2012, after Progenics had led its pre-clinical and early clinical development through 2011. In November 2018, the United States Adopted Names Council officially named PRO 140 as "leronlimab." The company's current business strategy involves continuing the clinical development of leronlimab. This includes ongoing efforts such as the Phase II trial of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer. CytoDyn Inc. and its wholly owned subsidiary, CytoDyn Operations Inc., are included in the consolidated financial statements. The principal business office is located at 1111 Main Street, Suite 660, Vancouver, Washington 98660.